Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2021 05:13 ET | Source: Research and Markets

United States Biodefense-Related Rapid Pathogen Identification and Treatments Markets Outlook Report: Data from 2019-2020, estimates for 2021 and CAGR projections to 2026

Dublin, Nov. 12, 2021 (GLOBE NEWSWIRE) -- The "The U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments 2021-2026" report has been added to ResearchAndMarkets.com's...
June 17, 2015 08:00 ET | Source: VaxInnate Corporation

VaxInnate Appoints Former CDC Division Chief Thomas Monath to Board of Directors

Cranbury, NJ, June 17, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology platform, today announced the appointment of Thomas P. Monath,...
May 13, 2015 08:00 ET | Source: Scienta Communications

VaxInnate Enhances R&D Program and Strengthens Senior Management Team to Drive Pipeline Development of Current and Potential Targets

Cranbury, NJ, May 13, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology, today announced two strategic promotions and two additions to...
April 07, 2015 08:00 ET | Source: VaxInnate Corporation

VaxInnate to Present at Needham & Company 14th Annual Healthcare Conference

Cranbury, NJ, April 7, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology, today announced plans to present at the Needham & Company 14th...
February 17, 2015 08:00 ET | Source: VaxInnate Corporation

VaxInnate Receives Extension of Contract from BARDA for Development of Seasonal and Pandemic Influenza Vaccines

Cranbury, NJ, Feb. 17, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology, today announced that it has executed a contract modification...
December 08, 2014 08:00 ET | Source: VaxInnate Corporation

VaxInnate Initiates Phase 1b/2 Clinical Trial of Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, in Elderly

Cranbury, NJ, Dec. 8, 2014 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology platform, today announced the initiation of a double-blind,...
August 26, 2013 08:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Announces Biosecurity Program to Potentially Reduce Pandemic Influenza Threat

PHILADELPHIA, Aug. 26, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced that at the 2nd International Conference on Biodefense and Natural Disasters meeting in Orlando, FL on August...
August 20, 2013 11:21 ET | Source: Hemispherx Biopharma, Inc.

Director of the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Professor J. Richt, DVM, Ph.D., to Present Programs to Reduce - Influenza Spread

PHILADELPHIA, Aug. 20, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that one of its advanced stage biological products, Alferon N®, will be featured as part of a new...